Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors

Medicine and Dentistry

• Adverse Event 100%
• Awareness 33%
• Cancer 33%
• Colitis 33%
• Disease Predisposition 33%
• Drug Megadose 33%
• Eosinophilic Fasciitis 33%
• Exanthem 33%
• Family History 33%
• Hypophysitis 33%
• Immune Checkpoint Inhibitor 100%
• Immunotherapy 100%
• Ipilimumab 33%
• Lung Biopsy 33%
• Lung Sarcoidosis 33%
• Malignant Neoplasm 100%
• Methotrexate 66%
• Monoclonal Antibody 33%
• Neoplasm 33%
• Nivolumab 33%
• Patient Registry 33%
• Pembrolizumab 33%
• Pneumonia 33%
• Psoriasis 33%
• Rheumatoid Arthritis 33%
• Side Effect 100%
• Steroid Therapy 33%
• T Cell Activation 33%
• Tumor Progression 33%
• Uveitis 33%

Keyphrases

• Biopsy-proven 20%
• Cancer Center 20%
• Cancer Patients 100%
• Colitis 20%
• Enhanced Awareness 20%
• Eosinophilic Fasciitis 20%
• Family History 20%
• Hepatitis 20%
• High-dose Steroids 20%
• Hypophysitis 20%
• Immune Checkpoint Inhibitors 100%
• Immune-related Adverse Events 60%
• Improved Survival 20%
• Inflammatory Arthritis 20%
• Ipilimumab 20%
• Israel 20%
• Malignancy 20%
• Methotrexate 20%
• Monoclonal Antibody 20%
• Nivolumab 20%
• Non-steroidal Anti-inflammatory Drugs (NSAIDs) 20%
• Patient Registry 20%
• Pembrolizumab 20%
• Personal History 20%
• Pneumonitis 20%
• Predisposing Factors 20%
• Psoriasis 20%
• Pulmonary Sarcoidosis 20%
• Rash 20%
• Rheumatic Manifestations 100%
• Side Effect Profile 20%
• Standard of Care 20%
• Steroid Therapy 20%
• Steroid-sparing 20%
• T Cell Activation 20%
• Tertiary Cancer Center 20%
• Tumor Progression 20%
• Tumor Response 20%
• Uveitis 20%

Immunology and Microbiology

• Awareness 33%
• Colitis 33%
• Drug Megadose 33%
• Eosinophilic Fasciitis 33%
• Hypophysitis 33%
• Immunotherapy 100%
• Inflammatory Arthritis 33%
• Ipilimumab 33%
• Methotrexate 66%
• Monoclonal Antibody 33%
• Nivolumab 33%
• Pembrolizumab 33%
• Pneumonitis 33%
• Sarcoidosis 33%
• T Cell Activation 33%
• Uveitis 33%